Onconova Therapeutics to Participate in Three Investment Conferences During the Month of March
March 01 2021 - 8:00AM
Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a
biopharmaceutical company focused on discovering and developing
novel products for patients with cancer, today announced that
Steven Fruchtman, M.D., President and Chief Executive Officer, will
participate in three virtual investment conferences during the
month of March, as follows:
- The H.C. Wainwright Global Life
Sciences Virtual Conference with one-on-one meetings being held
March 9-10, 2021
- The Virtual 33rd Annual Roth
Conference with one-on-one meetings being held March 15-17,
2021
- The Maxim Group Emerging Growth
Virtual Conference being held March 17-18, 2021 with one-on-one
meetings scheduled after the event
The Roth Capital Partners presentation will be
prerecorded and available in the Investors & Media section of
the Company’s website beginning today. Institutional and other
investors interested in scheduling a one-on-one meeting with
Onconova during any of these conferences should contact their sales
representative at the sponsoring investment bank.
About Onconova Therapeutics,
Inc. Onconova Therapeutics is a biopharmaceutical company
focused on discovering and developing novel products to treat
cancer. The Company has proprietary targeted anti-cancer agents
designed to disrupt specific cellular pathways that are important
for cancer cell proliferation.
Onconova’s novel, proprietary multi-kinase
inhibitor ON 123300 is planned to begin a dose-escalation and
expansion Phase 1 trial in the U.S. in the first half of 2021, and
a dose-escalation and expansion Phase 1 trial is currently underway
in China.
Onconova’s product candidate oral rigosertib is
currently in a dose-escalation and expansion Phase 1
investigator-initiated study targeting patients with KRAS+ lung
adenocarcinoma in combination with nivolumab. In addition, Onconova
has commenced preclinical work investigating rigosertib in
COVID-19.
For more information, please visit
www.onconova.com.
Forward-Looking StatementsSome
of the statements in this release are forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933, as
amended, Section 21E of the Securities Exchange Act of 1934, as
amended, and the Private Securities Litigation Reform Act of 1995,
and involve risks and uncertainties. These statements relate to
Onconova’s expectations regarding the registered direct offering,
its patents and clinical development plans including [patient
enrollment timelines and] indications for its product candidates.
Onconova has attempted to identify forward-looking statements by
terminology including "believes," "estimates," "anticipates,"
"expects," "plans," "intends," "may," "could," "might," "will,"
"should," "approximately" or other words that convey uncertainty of
future events or outcomes. Although Onconova believes that the
expectations reflected in such forward-looking statements are
reasonable as of the date made, expectations may prove to have been
materially different from the results expressed or implied by such
forward-looking statements. These statements are only predictions
and involve known and unknown risks, uncertainties, and other
factors, including the success and timing of Onconova's clinical
trials and regulatory agency and institutional review board
approvals of protocols, Onconova’s ability to continue as a going
concern, the need for additional financing, Onconova’s
collaborations, market conditions and those discussed under the
heading "Risk Factors" in Onconova's most recent Annual Report on
Form 10-K and quarterly reports on Form 10-Q. Any forward-looking
statements contained in this release speak only as of its date.
Onconova undertakes no obligation to update any forward-looking
statements contained in this release to reflect events or
circumstances occurring after its date or to reflect the occurrence
of unanticipated events.
Contact information
Company Contact:Avi
OlerOnconova Therapeutics, Inc.267-759-3680
ir@onconova.ushttps://www.onconova.com/contact/
Investor Contact:LHA Investor
Relations Kim Sutton Golodetz212-838-3777kgolodetz@lhai.com
Onconova Therapeutics (NASDAQ:ONTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Onconova Therapeutics (NASDAQ:ONTX)
Historical Stock Chart
From Sep 2023 to Sep 2024